天天舔天天爽_视频日韩_成人网线_天天草草草_免费一级在线观看_色综合色综合色综合色综合

美國PopGenTech
Population Genetics Technologies公司通過多組個體基因組的同步分析，生產可加速大規模群體研究的產品，諾貝爾獎得主Dr.SydneyBrenner是本公司的聯合創始人。我們的專利技術取代了原先的樣本準備步驟，成為下一代的DNA測序技術，它克服了禁錮發現的成本障礙和實踐約束。

The goal of developing personalised medicine is dependent on identifying individuals that are likely to benefit from treatment with a particular drug.
To achieve this, clinicians and pharmaceutical companies need a system for the rapid discovery of clinical biomarkers, such as genetic variants, that are associated with disease predisposition and drug efficacy or toxicity.

Clinical biomarkers are genetic signposts that point to our potential individual drug responsiveness or disease predisposition. These are frequently hidden among millions of insignificant gene variants. Simplistic predictions of a new age of personalised medicine, driven mainly by faster sequencing technology, underestimate the resource required to identify new clinical biomarkers.

Next generation sequencing companies are constantly increasing the speed of sequencing, however the value lies in understanding what sequencing results mean. Faster sequencing will make more studies feasible, but this will not identify individuals that might respond well to a drug or who are likely to develop a particular disease. Indeed, even if sequencing were free, these problems would not be solved.

We are addressing these problems using our unique proprietary technology, in combination with a tailored expert service offering, which enables large-scale genetic analysis to be conducted. By enabling researchers to accurately link genetic variation and disease manifestation or drug response, we will make it possible for healthcare providers to tailor their approaches for specific diseases at the level of the individual. This will drive the introduction of personalised medicine and facilitate the development of cost-effective healthcare approaches.

Population Genetics Technologies now provides an integrated and cost-effective route to genetic biomarker identification, accessible to both commercial and academic organisations. This ground-breaking approach represents a leap forward in the realisation of personalised medicine, as it will enable genetic variation to be accurately linked with phenotype.

Our potential has already been recognised
In 2005, PGT received a Strategic Translation Award from the Technology Transfer Fund at the Wellcome Trust, in recognition of our technology’s potential. In February 2008, following successful demonstration of our key technologies, we raised ￡3.8 million in venture capital funding to test the combination of these technologies in integrated workflows and to validate their use with small population samples. In May 2009, we received further investment in response to the successful scale-up and achievement of our commercialisation milestones. We have now established a number of academic and commercial collaborations and are seeking to build on these in order to maximise the potential of our commercial offerings.